Friday, October 2, 2026

Back to today

From X

SLS · short

Sellas Life Sciences Group I

SELLAS Life Sciences Group faces a short case arguing that even a strong clinical outcome does not support its current valuation.

Sarepta Risk and the FDA

Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.

Value Roundup

Talen’s post-bankruptcy nuclear assets, FREIT’s $22 Kushner bid and Calithera’s failed liquidation vote illustrate unusual small-cap…

Publications we follow

Every publication on this site, hand-picked.

110 publications

Newsletters 93

X accounts we follow

Every account on this site, hand-picked.

72 accounts

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.